Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Anlon Healthcare IPO is 40. Their analysis recommends Avoid, However active risk seekers can try for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 40 | Avoid, However active risk seekers can try |
[Dilip Davda] AHL is engaged in the manufacture and marketing of specialized APIs as per global standards. It claims to be the first one to manufacture Loxoprofen and related products. The company marked set back in its top line for FY24 following its registration process with Brazil. Based on its recent financial data, the IPO appears aggressively priced. Only well-informed/cash surplus investors may park moderate funds for long term. Read detail review...
Anlon Healthcare Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Anlon Healthcare | 6.38 | 6.38 | 20.18 | 25.51 | Standalone | ||
| Kronox Lab Sciences | 6.91 | 6.91 | 24.28 | 26.18 | 28.26 | 7.50 | Standalone |
| Acutaas Chemicals | 19.81 | 19.81 | 161.24 | 58.47 | 12.15 | 7.19 | Standalone |
| Supriya Lifeciences | 23.35 | 23.35 | 123.85 | 29.27 | 18.86 | 5.55 | Standalone |
All the financial information for listed industry peers mentioned above on a Standalone basis and is sourced from the 4th Quarterly and year ended results as available of the respective company for the year ended March 31, 2024 as available on the website of stock exchanges. The financial information of our Company is based on the restated Standalone financial information for the year ended March 31, 2025.
Notes:
Anlon Healthcare IPO Reviews, analysis and views by popular members. Read Anlon Healthcare Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Post Recommendation Manage Recommendations
Note:
RHP